tranexamic acid Tablets, film coated 500 mg, 1000 mg

Dossier type
EU CTD
Dossier status
Ready to file
Country of origin
European Union
GMP approvals
EU GMP
Unavailable markets
Vietnam
Comments
500 mg - available as OTC
Manufacturer #358
A pharmaceutical manufacturer based in the EU that is active in 70+ countries worldwide selling its products in the EU, Australia, Pacific region, and Asia for 30+ years. The company owns several manufacturing plants that comply with EU GMP requirements with production facilities for Rx products, OTC products, nutraceuticals, and medical devices. Its key therapy areas are diabetology, oncology, and neuropsychiatry. The company possesses several R&D centers with hundreds of patents and provides e-CTD format dossiers.

Manufacturer usually replies in 22 days

Tranexamic acid is a coagulation modifier class medication that is used to prevent blood loss after major trauma, factor IX deficiency, hemophilia type A, melasma, nosebleeds, menorrhagia, and menstrual disorders. Manufacturing companies produce it as both standalone medication and in combination drug formulations, along with ingredients such as etamsylate and mefenamic acid. Suppliers market it in the forms of 100mg/ml solution for intravenous injection and 500mg tablets. In use for over 50 years, tranexamic acid is an inexpensive and widely used treatment. The World Health Organisation has included it in its list of Essential Medicines that contains the safest and most effective drugs recommended for a health system. Major pharmaceutical manufacturers and supplies of tranexamic acid include Pfizer and Sanofi-Aventis. Tranexamic acid is available in both trade name and generic formulations. Buyers are advised that online sellers may attempt to market fraudulent versions of the generic drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.